General Information |
| Board Constituency: |
None |
| Is your organization legally registered in your country: |
Yes |
| If yes, please enter your registration number: |
Delaware SR 20185845784 |
| Organization Type - Primary: |
Private Sector |
| Organization Type - Secondary: |
Company |
| Organization Description: |
| Pulmonescence Diagnostics is developing a simple, low-cost, revolutionary TB diagnostic that not only tracks, detects and diagnoses tuberculosis with a sensitivity beyond existing technologies but also incorporates a drug sensitivity test in the same test. |
| |
| Do you know about the UNHLM declaration: |
Yes |
Other Organization Information |
| Total number of staff in your organization: |
1 - 5 |
| Number of full-time staff who are directly involved with TB: |
1 - 5 |
| Number of part-time staff who are directly involved with TB: |
0 |
| Number of volunteers who are directly involved with TB: |
0 |
| |
| How did you hear about the Stop TB Partnership: |
Internet search |
| If you were informed or referred by another partner of the Stop TB Partnership please tell us who: |
|
| Why do you wish join the Stop TB Partnership: |
Network with other partners |
| |
| Are you a member of a Stop TB national partnership: |
No |
| Are you in contact with your national TB programme: |
No |
| Please tell us how your organization is contributing to your country's national TB control plan: |
| Pulmonescence Diagnostics is working to advance a low-cost point-of- care diagnostic system, designated reporter enzyme fluorescence for TB (REFtb), a rapid POC diagnostic system for tuberculosis that can also identify drug resistant strains in limited-resource settings with minimal specialized training or limited logistic assistance. |
| |
Geographical Reach |
| Which country is your headquarters located in: |
United States of America |
Which countries do you do operate in:
(This includes countries you are conducting activities in) |
Unknown |
